By Loraine Aceto
The number of people with Alzheimer’s worldwide is estimated as high as 24 million, and the frequency is expected to double every 20 years until 2040, According to the US National Library of Medicine at the National Institutes of Health. The Yale Alzheimer’s Disease Research Center found that binding amyloid beta peptides to prion proteins (misfolded proteins which identify with neurodegenerative diseases) slows down the start of Alzheimer’s. Binding these two reduces the symptoms of accumulation of plaques, a destructive immune system response and damage to synapses. This finding just keeps getting better and better as Yale researchers pinpointed a cocktail with designer molecules that stops the first steps of early Alzheimer’s.
The director of the Yale Alzheimer’s Disease Research Center is Stephen Strittmatter, MD, PhD, a professor of neuroscience. Strittmater, who could be consider the Vincent Coates of neurology, and research scientist Erik Gunther screened the higher end of the range of 20,000 to 100,000 compounds researching for molecules that might put a stop to the bad, harmful prion protein (misfolded protein identified with neurodegenerative diseases) interaction with amyloid beta (this beta is good and helpful to stop Alzheimer’s beginnings).
An old antibiotic looked like a support to cure Alzheimer’s beginning stages; this antibiotic can only be active after decomposing to form a polymer which is only the processing of it but still quite helpful to cure the beginning of Alzheimer’s. Associated small polymers continued to be beneficial to cure the first steps of Alzheimer’s and “also managed to pass through the blood-brain barrier,” according to Yale. The researchers “then dissolved the optimized polymeric compound and fed it to mice engineered to have a condition that mimics Alzheimer’s. They found that synapses in the brains were repaired and mice recovered lost memory,” according to Yale.
Dartmouth College experimented with applying the exact cocktail to cells modeled containing Creutzfeldt-Jakob disease, a neurological condition caused by infection with misfolded prion proteins, and the cocktail with the molecules that was examined by Yale cured the first steps of Creutzfeldt-Jakob Disease as well.
Yale is authenticating that these compounds are not harmful before they prepare to send their discoveries to clinical trials for Alzheimer’s Disease to transfer. This might be the next step for Alzheimer’s, helping thousands, millions, billions of people make history. We might not have to worry about our grandparents or anyone having Alzheimer’s anymore if this treatment passes as nontoxic. The hope of that is amazing.